K Torizuka
About
In The Last Decade
K Torizuka
296 papers receiving 4.6k citations
Peers
Comparison fields: 5 of 136
- Radiology, Nuclear Medicine and Imaging 1.9k
- Endocrinology, Diabetes and Metabolism 1.4k
- Surgery 794
- Pulmonary and Respiratory Medicine 743
- Molecular Biology 651
Countries citing papers authored by K Torizuka
This map shows the geographic impact of K Torizuka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Torizuka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Torizuka more than expected).
Fields of papers citing papers by K Torizuka
This network shows the impact of papers produced by K Torizuka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Torizuka. The network helps show where K Torizuka may publish in the future.
Co-authorship network of co-authors of K Torizuka
This figure shows the co-authorship network connecting the top 25 collaborators of K Torizuka. A scholar is included among the top collaborators of K Torizuka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Torizuka. K Torizuka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Updating Cardiopulmonary Resuscitation | 0 |
| 2 | 2 | |
| 3 | [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 1)--report on clinical usefulness in diagnosis of various brain diseases]. | 4 |
| 4 | [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 2)--Report on clinical usefulness in diagnosis of degenerative neurological diseases and mental disorders]. | 3 |
| 5 | [A phase 3 clinical trial of 123I-iomazenil, a new central-type benzodiazepine receptor imaging agent (Part 3)--Report on clinical usefulness in epilepsy]. | 2 |
| 6 | Clinical usefulness of thallium-201 chloride in the diagnosis of tumor, (2) | 2 |
| 7 | [A phase 2 clinical study of 99mTc-MAG3 injectable a dynamic renal imaging agent--evaluation of its safety, effectiveness and optimal dose]. | 0 |
| 8 | [Phase 3 study of beta-methyl-p-(123I)-iodophenyl-pentadecanoic acid, a myocardial imaging agent for evaluating fatty acid metabolism--a multi-center trial]. | 10 |
| 9 | [A multi-center clinical trial on 99mTc-DTPA-HSA, a new radiopharmaceutical for cardiovascular system imaging]. | 0 |
| 10 | Development of a new sensitive immunoradiometric assay for CA125: Mixed use of two monoclonal antibodies reactive with separate epitopes | 7 |
| 11 | [Value of regional cerebral perfusion SPECT with N-isopropyl-(I-123)p-iodoamphetamine (IMP) in brain tumors]. | 1 |
| 12 | 1 | |
| 13 | [Significance of Ga-67-citrate tomographic scan in renal cell carcinoma]. | 2 |
| 14 | Non-invasive diagnosis of a false left ventricular aneurysm with radionuclide ventriculography. | 1 |
| 15 | THE CAUSATIVE MECHANISMS OF MITRAL VALVE PROLAPSE IN PROGRESSIVE MUSCULAR DYSTROPHY : THORAX AND THORACIC SPINE DEFORMITY AND LEFT VENTRICULAR DYSFUNCTION : Cardiomyopathy (I) : 46th Annual Scientific Meeting, Japanese Circulation Society | 1 |
| 16 | 3 | |
| 17 | [Clinical feature and calcitonin therapy on Paget's disease of bone (author's transl)]. | 1 |
| 18 | Quantitative assessment of ventilation-perfusion mismatch by radioxenon imaging of the lung. | 7 |
| 19 | Tumor imaging after administration of 99mTc-labeled bleomycin. | 19 |
| 20 | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.